Search Results

Shape Memory Medical Inc. announced the first patient treated as part of the AAA-SHAPE Pivotal Trial, the Company’s prospective, multicenter, randomized, open-label trial to determine safety and effectiveness of the IMPEDE-FX RapidFill® Device to improve abdominal aortic aneurysm (AAA) sac behavior when used with elective endovascular aneurysm repair (EVAR).

Shape Memory Medical Inc., developer of custom shape memory polymers for endovascular markets, announced today that it has completed $38 million in Series C financing.

Shape Memory Medical Inc., developer of shape memory polymer for peripheral and neurovascular markets, announced the publication of results from the Company’s prospective, open-label, single-arm, safety study of the IMPEDE Embolization Plug in peripheral vascular embolization.

Shape Memory Medical Inc announced that the Food and Drug Administration (FDA) granted investigational device exemption (IDE) for the company to begin a prospective, multicenter, randomized, open-label trial to determine safety and effectiveness of the IMPEDE-FX RapidFill® Device to improve abdominal aortic aneurysm (AAA) sac behavior when used with elective endovascular aneurysm repair (EVAR).

In this episode, Lori and guests discuss the pursuit of adequate representation and how clinical trials are being shaped by the legal environment they operate within.

OASIS® Medical Inc., manufacturer and distributor of disposable surgical solutions and dry eye solution brands Oasis TEARS® and SOFT PLUG® punctal plugs launch the SOFT PLUG® Extended Duration 180-T Tapered Plug at ASCRS booth 2675 in Boston.

3Shape announces the launch of three exciting solutions at its 3Shape Discover digital dentistry event.

Shape Therapeutics, Inc., a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, announces the appointments of David Epstein, former CEO of Seagen, and Todd Simpson, former CFO of Seagen, to its board of directors.

Shape Therapeutics Inc., a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the appointment of Matt Valentino as Chief People Officer.